The association between post-progression survival and clinical characteristics of patients with metastatic colon cancer: A single center experience

dc.authorscopusid57327137700
dc.authorscopusid57205580317
dc.authorscopusid57193238894
dc.authorscopusid55987915300
dc.authorscopusid57207826720
dc.authorscopusid7006046625
dc.contributor.authorOzekin M.E.
dc.contributor.authorGokyer A.
dc.contributor.authorKucukarda A.
dc.contributor.authorKostek O.
dc.contributor.authorIssever K.
dc.contributor.authorErdogan B.
dc.date.accessioned2024-06-12T10:28:26Z
dc.date.available2024-06-12T10:28:26Z
dc.date.issued2021
dc.description.abstractPurpose: In this study, we aimed to determine the factors which affect post-progression survival (PPS) and overall survival (OS) in patients with metastatic colorectal cancer. Methods: 87 patients with metastatic colorectal cancer had been followed up with palliative care due to disease progression 7or ECOG performance status after receiving at least two cycles of chemotherapy. PPS was estimated as the time between the last progression date and last control or death date in patients who were followed up with palliative care. Results: 87 patients with metastatic colorectal cancer were included in the study. Evaluation with multivariate analysis of factors affecting PPS revealed a significantly longer PPS (10.8 weeks) in patients with ECOG score 0 or 1 than the PPS of patients with ECOG score 2-5 (3 weeks) (p=0.01). It was also found that PPS was 14.4 weeks in patients with CEA levels <5ng/ml,while it was 6.7 weeks in patients with CEA levels >5 ng/ml (p=0.001) and PPS was 13.7 weeks in patients with controlled disease after first-line chemotherapy while it was 8 weeks in patients with progression (p=0.03); both were statistically significant. No significant association was found between PPS and age, gender, tumor location, sites of metastasis, and RAS status. Conclusion: ECOG performance status score of 0-1, CEA levels below 5 ng/ml, and disease control with first-line chemotherapy are related to longer PPS in patients with metastatic colorectal cancer. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage1892en_US
dc.identifier.issn1107-0625
dc.identifier.issue5en_US
dc.identifier.pmid34761596en_US
dc.identifier.scopus2-s2.0-85118757974en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1887en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17253
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal Cancer; Overall Survival; Post-Progression Survivalen_US
dc.subjectAntineoplastic Agent; Carcinoembryonic Antigen; Ras Protein; Adult; Article; Cancer Chemotherapy; Cancer Control; Cancer Growth; Carcinomatous Peritonitis; Clinical Feature; Death; Ecog Performance Status; Female; Gender; Gene Mutation; Human; Liver Metastasis; Lung Metastasis; Major Clinical Study; Male; Metastatic Colon Cancer; Multiple Cycle Treatment; Overall Survival; Palliative Therapy; Progression Free Survival; Retrospective Study; Tumor Localization; Aged; Colorectal Tumor; Disease Exacerbation; Metastasis; Middle Aged; Mortality; Pathology; Survival Rate; Aged; Colorectal Neoplasms; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rateen_US
dc.titleThe association between post-progression survival and clinical characteristics of patients with metastatic colon cancer: A single center experienceen_US
dc.typeArticleen_US

Dosyalar